Want to join the conversation?
The pharmacy benefit manager $ESRX reported 3Q15 net income of $661.7MM or $0.97 per diluted share. $ESRX said it had revenue of $25.22Bil compared to $25.77Bil in the prior year period. Adjusted claims during the quarter were 328.3MM and adjusted EBITDA was $1,808.3MM, up 4% YoverY.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.
Well this is big! I don’t know if it’s someone’s monopoly or genuine excitement, but either way, $CSX is up 23% after market closed. I heard some activist investor is going to blow big money into CSX Corp. Anyone mind explaining?